DBV Technologies | DBVT - Debt

Stock Price
19.74
Daily Change
-0.62 -3.02%
Monthly
-4.64%
Yearly
321.79%
Q1 Forecast
19.99

DBV Technologies reported $8.59M in Debt for its fiscal quarter ending in September of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 54.81M 1.48M Sep/2025
Alnylam Pharmaceuticals USD 1.31B 11.39M Sep/2025
Amarin USD 0 0 Mar/2025
BioCryst Pharmaceuticals USD 828.6M 510K Dec/2024
BioMarin Pharmaceutical USD 604.24M 375K Sep/2025
DBV Technologies USD 8.59M 295K Sep/2025
Esperion Therapeutics USD 262.92M 1.76M Sep/2024
Galectin Therapeutics USD 71.74M 10.6M Dec/2023
Halozyme Therapeutics USD 1.51B 1.66M Sep/2025
Incyte USD 40.41M 855K Dec/2025
Insmed USD 727.89M 163.33M Dec/2025
Ionis Pharmaceuticals USD 2.33B 1.1B Dec/2025
Neurocrine Biosciences USD 428.4M 10.7M Sep/2025
PTC Therapeutics USD 286.32M 306K Sep/2025
Sarepta Therapeutics USD 1.25B 103.69M Sep/2025
Ultragenyx Pharmaceutical USD 33.83M 2.46M Sep/2025
United Therapeutics USD 200M 100M Mar/2025